IMP: 2024 Annual Report
Filed with HOSE · · 113 pages · English and Vietnamese
Summary by 6ix AI
The report outlines significant achievements, including revenue growth and advancements in research and development, while maintaining its leadership position in the market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
01 TỔNG QUAN IMEXPHARM 02 ĐỊNH HƯỚNG PHÁT TRIỂN 03 BÁO CÁO HOẠT ĐỘNG NĂM 2024 04 QUẢN TRỊ CÔNG TY 05 PHÁT TRIỂN BỀN VỮNG 06 BÁO CÁO TÀI CHÍNH Imexpharm’s 2024 Annual Report presents a bold and forward-thinking perspective, embodying our pioneering spirit and commitment to lasting progress. Under the theme “Connecting Science-Resilient Growth”, this year’s report is brought to life with dynamic vis
Story so far
Earlier from Imexpharm
- IMP: 2023 Annual Report
- IMP: 2025 Annual Report
- IMP: Record date for 2025 cash dividend payment
- IMP: Notice of the record date for 2025 cash dividend payment
- IMP: Approval of the record date for 2025 cash dividend payment
Later from Imexpharm
- IMP: Report on Corporate Governance for the first half of 2026
- IMP: The Board resolution dated September 7, 2026
- IMP: Update Regulations on Supervision and Approval of related party transactions
- IMP: Update Regulations on the Internal Audit
- IMP: Update Regulations on the Operation of the audit & Risk Management Committee
Follow Imexpharm into a list and get an email when it puts out news.
Follow Imexpharm